®®Hibbs brings more than 25 years of legal and management expertise in clinical diagnostic market segment to Cadex Genomics
REDWOOD CITY, California - October 18, 2019 – Cadex Genomics, developers of a real-time cancer therapy monitoring diagnostic, Alibrex, today announced the election of Kathy Hibbs, Esq. as an independent director.
Hibbs is the chief legal and regulatory officer at 23andMe. Prior to joining 23andMe, Hibbs served as senior vice president and general counsel, responsible for the legal, regulatory and business development functions at Genomic Health, Inc. Hibbs has also held related posts at Monogram Biosciences Inc., and Varian Medical Systems, Inc.
Hibbs is active in several industry groups, including AdvaMed and the Personalized Medicine Coalition (PMC). Hibbs holds a Juris Doctorate from the University of California, Hastings School of Law and a Bachelor of Arts in political science from the University of California, Riverside.
"We are extremely pleased to have Kathy join our board,” said Bill Haack, president and CEO of Cadex Genomics. “Kathy brings a depth of leadership, knowledge and experience that will be invaluable to us as we approach the commercialization phase of the company.”
About Alibrex™
Alibrex is a patented technology that detects, with great analytical precision, retrotransposon elements found on all 23 chromosomes. Alibrex enables testing with most tumor types. Alibrex is based on qPCR technology enabling fast turnaround time.
About Cadex Genomics™
Cadex Genomics is a privately held molecular diagnostic assay company based in Redwood City, California that is improving cancer patient outcomes by providing physicians with better diagnostic tools to guide treatment.
For more information, please visit our website https://cadexgenomics.com.
Alibrex and Cadex Genomics are trademarks of Cadex Genomics, Corp.